EUVIMEDEUVIMED entdecken
Crossref

Indian Perspective on Antiplatelet De-escalation from Dual Antiplatelet Therapy to Single Antiplatelet Therapy – INDEPTH INSIGHT Survey

Jagdish Chander Mohan, Abraham Oomman, V T Shah, Baishali Nath

Cardiology and Cardiovascular Medicine · 2026 · 10 (3)

DOI: 10.26502/fccm.92920490 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiology and Cardiovascular Medicine, 2026. Verfasst von Jagdish Chander Mohan und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dual antiplatelet therapy (DAPT) is used for secondary prevention after percutaneous coronary intervention (PCI), but prolonged use raises bleeding risk.De-escalation to single antiplatelet therapy balances ischemic protection and safety.

Objective

This study aimed to assess cardiologists' knowledge, decisionmaking, treatment preferences and prescribing behaviors related to antiplatelet de-escalation in the Indian context.

Methods

A cross-sectional survey involving 384 Indian cardiologists with 18 questions assessed awareness of genetic and platelet testing, de-escalation, clopidogrel resistance, and adverse events.Participation was voluntary, and responses were analyzed descriptively to reduce bias.

Results

The survey demonstrated that 46.9% considered genetic testing relevant.However, its routine use remains limited, with greater reliance on platelet function testing (64.3%) and clinical judgement.High bleedingrisk (HBR) patients without genetic testing often switch to clopidogrel after 1-3 months (62.0%), while non-HBR patients typically use ticagrelor/prasugrel for 12 months (52.3%).Management of clopidogrel resistance followed guidelines, with 76.3% switching to another P2Y12 inhibitor.Most reported occasional (35.4%) transitions to prasugrel/ ticagrelor, while ticagrelor-to-clopidogrel switches were rare (38.5%).Adverse events (AEs) prompted therapy changes, with dyspnea (58.6%) being most common, leading to switching to clopidogrel.Major bleeding (70.4%), age ≥75 (39.2%), and low body weight (

Zitieren

APA

Mohan, J. C., Oomman, A., Shah, V. T., & Nath, B. (2026). Indian Perspective on Antiplatelet De-escalation from Dual Antiplatelet Therapy to Single Antiplatelet Therapy – INDEPTH INSIGHT Survey. Cardiology and Cardiovascular Medicine, 10(3). https://doi.org/10.26502/fccm.92920490

Vancouver

Mohan JC, Oomman A, Shah VT, Nath B. Indian Perspective on Antiplatelet De-escalation from Dual Antiplatelet Therapy to Single Antiplatelet Therapy – INDEPTH INSIGHT Survey. Cardiology and Cardiovascular Medicine. 2026;10(3). doi:10.26502/fccm.92920490

BibTeX
@article{Mohan2026,
  author = {Mohan, Jagdish Chander and Oomman, Abraham and Shah, V T and Nath, Baishali},
  title = {Indian Perspective on Antiplatelet De-escalation from Dual Antiplatelet Therapy to Single Antiplatelet Therapy – INDEPTH INSIGHT Survey},
  journal = {Cardiology and Cardiovascular Medicine},
  year = {2026},
  volume = {10},
  number = {3},
  doi = {10.26502/fccm.92920490}
}
Kostenlos starten →